Share This Page
Drug Price Trends for URO-PAIN
✉ Email this page to a colleague
Average Pharmacy Cost for URO-PAIN
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| URO-PAIN 99.5 MG TABLET | 57237-0330-21 | 0.18720 | EACH | 2026-05-20 |
| URO-PAIN DUAL 162-162.5 MG TAB | 57237-0332-42 | 0.17764 | EACH | 2026-05-20 |
| URO-PAIN 99.5 MG TABLET | 57237-0330-42 | 0.18720 | EACH | 2026-05-20 |
| URO-PAIN 95 MG TABLET | 57237-0331-03 | 0.13348 | EACH | 2026-05-20 |
| URO-PAIN 99.5 MG TABLET | 57237-0330-21 | 0.19056 | EACH | 2026-04-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
URO-PAIN: Market analysis and price projections
URO-PAIN is not a uniquely identifiable, regulatorily defined drug name in the public domain. With no reliable mapping to a specific active ingredient, dosage form, route, strength, or approved jurisdiction, a defensible market sizing and price-projection exercise cannot be produced without risking materially incorrect conclusions.
What cannot be established from available identifiers
- Active ingredient: not specified
- Dosage form and route: not specified
- Strengths: not specified
- Indication(s): not specified
- Regulatory status (FDA/EMA/UK/MENA/etc.): not specified
- Reference products for pricing: not specified
- Formulary context (payers, reimbursement rules): not specified
Given these missing anchor points, any market analysis would be speculative, not analytical.
Can URO-PAIN be priced and forecast without an identifiable product?
No. URO-PAIN cannot be linked to a single product profile (ingredient, strength, form, and label claim) that is required to:
- derive a launch and adoption curve,
- select comparable products (therapeutic class, mechanism, and dosing regimen),
- estimate net price (WAC to AMP/MRP/CIP equivalents),
- model payer reimbursement and patient share,
- project unit volumes from epidemiology and treatment rates.
What market inputs are required for a price projection model?
A complete pricing forecast typically needs the following, all tied to a specific product profile:
Commercial and pricing
- Gross-to-net bridge inputs (rebates, discounts, fees)
- Pricing basis by jurisdiction (WAC vs AWP vs MRP vs ex-factory)
- Demand elasticity and sensitivity by payer segment
- Competitive intensity (number of brands, generics, and substitutes)
Therapeutic and demand
- Indication definition and treated population size
- Line-of-therapy distribution
- Dosing frequency and duration
- Treatment switching triggers
Regulatory and access
- Label scope and whether it is restricted or unrestricted
- Formulary placement (preferred vs non-preferred)
- Prior authorization and step edits
Without an identifiable URO-PAIN product definition, none of these can be grounded to verifiable facts.
Price projection framework (what would be used once product identity is established)
The below is the structure required for an investment-grade forecast; it is not filled with numbers because URO-PAIN’s product identity is not specified.
Step 1: Establish price reference points
- Benchmark against 2 to 6 comparable branded therapies in the same indication and dosing model
- Add generic and OTC substitutes where applicable
- Convert all benchmarks to a single currency basis and price concept (ex-factory or net)
Step 2: Build a launch-to-peak adoption curve
- Years 1 to 5 unit penetration by channel (hospital vs retail, if relevant)
- Uptake drivers (payer coverage, clinical guidelines, formulary timing)
- Retention (persistence) based on dosing practicality and tolerability
Step 3: Compute net revenue and derive price
- Net price per unit from gross-to-net bridge
- Net revenue = units * net price
- Reverse-engineer implied net price if sales projections exist, or estimate forward from price assumptions
Step 4: Scenario analysis
- Downside: payer restrictions and fast generic/therapeutic substitution
- Base: formulary coverage consistent with class norms
- Upside: stronger-than-expected adoption and restricted competitor access
Comparable-product table (cannot be completed for URO-PAIN)
A comparable table requires:
- active ingredient or ATC/therapeutic class mapping
- formulation type (oral tablet, capsule, injection, topical, etc.)
- typical dose and daily cost drivers
Those inputs are absent for URO-PAIN, so a comparable pricing set cannot be produced without fabrication.
| Field | Required to proceed | Current status for URO-PAIN |
|---|---|---|
| Ingredient | Match to ATC and substitutes | Not provided |
| Form/route | Select dosing and substitution set | Not provided |
| Strength | Unit economics and benchmark alignment | Not provided |
| Indication | Demand size and payer rules | Not provided |
| Jurisdiction | Pricing basis and taxes/fees | Not provided |
What you can’t treat as reliable: generic price ranges by “drug name”
Even where a name sounds like an indication (for example, pain or urology), drug name-based pricing can be wrong because:
- multiple different actives can share similar brand naming,
- combination products change cost per course materially,
- dosing frequency varies by formulation,
- reimbursement rules differ by indication scope and jurisdiction.
For a price projection to be actionable, it must tie to the correct product profile.
Key Takeaways
- URO-PAIN cannot be used for a defensible market analysis or price projection without an unambiguous mapping to active ingredient, dosage form, strength, route, indication, and regulatory context.
- Any numeric forecast would require fabricating product identity, comparable products, and pricing basis, which would invalidate the analysis for R&D or investment decisions.
FAQs
-
Is URO-PAIN an FDA-approved drug name?
Not determinable from the provided identifier alone. -
Can a price forecast be built using only the brand name?
No. Pricing forecasts require product-level identity and pricing basis by jurisdiction. -
What definition is required for market sizing?
Indication scope, treated population proxy, and dosing regimen tied to the exact active ingredient and formulation. -
What benchmarks does a pricing model use?
Comparable branded therapies and substitutes matched by indication, dosing model, and reimbursement environment. -
Can I get a numeric projection now?
No valid numeric projection can be produced without reliable product identity for URO-PAIN.
References
[1] No sources cited because URO-PAIN’s active ingredient, formulation, indication, and regulatory identity are not provided in the prompt.
More… ↓
